Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia

Most patients with acute myelogenous leukemia (AML) relapse and die of their disease. Increasing evidence indicates that AML relapse is driven by the inability to eradicate leukemia stem cells (LSC). Thus, it is imperative to identify novel therapies that can ablate LSCs. Using an in silico gene exp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Guzman, Monica L., Yang, Neng, Sharma, Krishan K., Balys, Marlene, Corbett, Cheryl A., Jordan, Craig T., Becker, Michael W., Steidl, Ulrich, Abdel-Wahab, Omar, Levine, Ross L., Marcucci, Guido, Roboz, Gail J., Hassane, Duane C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4383047/
https://ncbi.nlm.nih.gov/pubmed/24934933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-13-0963
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados